专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060229270A1 Methods of treating proteinuria by reducing double-stranded DNA antibodies 审中-公开
标题翻译：通过减少双链DNA抗体治疗蛋白尿的方法
公开(公告)号：US20060229270A1
公开(公告)日：2006-10-12
申请号：US11373699
申请日：2006-03-10
申请人： Matthew Linnik
发明人： Matthew Linnik
IPC分类号： A61K48/00 , C12N15/88
CPC分类号： A61K47/60
摘要： The invention provides methods of treating proteinuria in an individual such as human by administering an effective amount of an agent that reduces the level of anti-dsDNA antibodies (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) to the individual. The invention also provides methods of determining responsiveness of the individual to (or selecting an individual for continuing) treatment of an agent that reduces anti-dsDNA antibodies by determining reduction of proteinuria after a certain period of time upon initiation of the treatment.
摘要翻译：本发明提供了通过施用有效量的降低抗dsDNA抗体水平的试剂（例如以表位呈递载体或表位 - 表达载体的形式存在的dsDNA表位）来治疗个体（例如人）中的蛋白尿的方法，呈现价格平台分子，如LJP 394）给个人。本发明还提供了确定个体对（或选择个体继续）治疗反应性的方法，所述方法通过在开始治疗一定时间后确定蛋白尿的减少来降低抗dsDNA抗体。

2. 发明申请

US20070179111A1 METHODS OF TREATING PROTEINURIA BY REDUCING DOUBLE-STRANDED DNA ANTIBODIES 审中-公开
标题翻译：通过减少双链DNA抗体来治疗蛋白质的方法
公开(公告)号：US20070179111A1
公开(公告)日：2007-08-02
申请号：US11613987
申请日：2006-12-20
申请人： Matthew LINNIK
发明人： Matthew LINNIK
IPC分类号： A61K48/00
CPC分类号： A61K47/60
摘要： The invention provides methods of treating proteinuria in an individual such as human by administering an effective amount of an agent that reduces the level of anti-dsDNA antibodies (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) to the individual. The invention also provides methods of determining responsiveness of the individual to (or selecting an individual for continuing) treatment of an agent that reduces anti-dsDNA antibodies by determining reduction of proteinuria after a certain period of time upon initiation of the treatment.
摘要翻译：本发明提供了通过施用有效量的降低抗dsDNA抗体水平的试剂（例如以表位呈递载体或表位 - 表达载体的形式存在的dsDNA表位）来治疗个体（例如人）中的蛋白尿的方法，呈现价格平台分子，如LJP 394）给个人。本发明还提供了确定个体对（或选择个体继续）治疗反应性的方法，所述方法通过在开始治疗一定时间后确定蛋白尿的减少来降低抗dsDNA抗体。

3. 发明申请

US20060217333A1 Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function 审中-公开
公开(公告)号：US20060217333A1
公开(公告)日：2006-09-28
申请号：US11347426
申请日：2006-02-02
申请人： Matthew Linnik , Bonnie Hepburn , Robert Bagin
发明人： Matthew Linnik , Bonnie Hepburn , Robert Bagin
IPC分类号： A61K48/00 , C07H21/02
CPC分类号： A61K48/005 , C12N15/87
摘要： The invention provides methods treating lupus nephritis based in individuals with significantly impaired renal function, and methods of selecting individuals for treatment based on significantly impaired renal function. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient. The invention also provides methods of identifying individuals suitable for treatment for lupus, based on assessing renal function to identify those individuals with significant impairment of renal function.

4. 发明申请

US20050004351A1 Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same 审中-公开
标题翻译：治疗和诊断领域1β2GP1多肽及其使用方法
公开(公告)号：US20050004351A1
公开(公告)日：2005-01-06
申请号：US10903058
申请日：2004-07-30
申请人： David Marquis , Gilbert Iverson , Edward Victoria , David Jones , Matthew Linnik
发明人： David Marquis , Gilbert Iverson , Edward Victoria , David Jones , Matthew Linnik
IPC分类号： G01N33/68 , A61K38/00 , A61K39/385 , A61K47/48 , A61P37/02 , C07D295/185 , C07K14/47 , C07K14/775 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C07K16/42
CPC分类号： C07D295/185 , A61K47/60 , C07C271/16 , C07K14/4713 , C07K14/775 , Y10S435/975
摘要： The present invention provides domain 1 β2GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β2GPI polypeptides and mimetics. Domain 1 of β2GPI has been shown to bind to anti-cardiolipin (β2GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 β2GPI polypeptides may be used to detect β2GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 β2GPI polypeptides.
摘要翻译：本发明提供了结构域β2GPI多肽，编码这些多肽的多核苷酸，这些多肽的模拟物，以及使用结构域β2GPI多肽和模拟物的方法。已经显示β2GPI的结构域1与抗心磷脂（β2GPI依赖性抗磷脂）抗体结合，其与几种病理学相关，例如血栓形成和胎儿丧失。结构域1β2GPI多肽可用于检测样品中的β2GPI依赖性抗磷脂抗体。本发明还提供了使用这些结构域1β2GPI多肽诱导耐受性的方法。

5. 发明申请

US20070293548A1 Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases 审中-公开
标题翻译：氨基脲敏感性胺氧化酶（SSAO）和VAP-1介导的粘附抑制剂可用于治疗和预防疾病
公开(公告)号：US20070293548A1
公开(公告)日：2007-12-20
申请号：US11731819
申请日：2007-03-30
申请人： Eric Wang , David Jones , Anne O'Rourke , Mary MacDonald , Hongfeng Gao , Huong-thu Ton-Nu , Christina Kessler , Matthew Linnik
发明人： Eric Wang , David Jones , Anne O'Rourke , Mary MacDonald , Hongfeng Gao , Huong-thu Ton-Nu , Christina Kessler , Matthew Linnik
IPC分类号： A61K31/44 , A61K31/135 , A61K31/343 , A61P37/00 , C07C211/29 , C07C217/54 , C07C211/26 , A61P29/00 , A61K31/381
CPC分类号： C07C217/62 , A61K31/137 , A61K31/138 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/4402 , A61K31/4406 , A61K31/47 , C07C211/28 , C07C211/29 , C07C255/58 , C07C317/32 , C07C323/32 , C07C2601/02 , C07D213/38 , C07D213/65 , C07D215/12 , C07D307/52 , C07D307/81 , C07D333/20 , C07D333/28 , C07D333/58
摘要： Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.
摘要翻译：提供了使用组合物治疗炎性疾病和免疫疾病的组合物和方法。公开了作为氨基脲敏感性胺氧化酶（SSAO）和/或血管粘附蛋白1（VAP-1）的抑制剂的烯丙基氨基化合物。这些化合物具有抑制炎症和炎症反应以及治疗多种疾病（包括多发性硬化和中风）的治疗效用。

6. 发明申请

US20060142229A1 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof 审中-公开
公开(公告)号：US20060142229A1
公开(公告)日：2006-06-29
申请号：US11081309
申请日：2005-03-15
申请人： Matthew Linnik , Patricia McNeeley
发明人： Matthew Linnik , Patricia McNeeley
IPC分类号： A61K48/00
CPC分类号： A61K47/549 , A61K38/00
摘要： The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient.

7. 发明申请

US20070218072A1 METHODS OF IMPROVING HEALTH-RELATED QUALITY OF LIFE IN INDIVIDUALS WITH SYSTEMIC LUPUS ERYTHEMATOSUS 审中-公开
标题翻译：改善身体健康相关生活质量的方法与系统性红斑狼疮
公开(公告)号：US20070218072A1
公开(公告)日：2007-09-20
申请号：US11562174
申请日：2006-11-21
申请人： Vibeke Strand , Matthew Linnik , Tenshang Joh
发明人： Vibeke Strand , Matthew Linnik , Tenshang Joh
IPC分类号： A61K39/385 , A61K39/00
CPC分类号： A61K31/70
摘要： The invention provides methods for stabilizing or improving the health-related quality of life in individuals with SLE, and methods of selecting individuals suitable for such treatment. One method of stabilizing or improving the health-related quality of life of an individual with SLE involves the administration of an effective amount of dsDNA epitope, such as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394, to the individual. The invention further provides a method of stabilizing or improving the health-related quality of life of an individual with SLE involving the reduction of the level of SLE-associated antibodies in the individual, optionally through administration of a dsDNA epitope to the individual. In addition, methods of screening patients are provided. Kits useful in the methods of the invention are also provided.
摘要翻译：本发明提供用于稳定或改善具有SLE的个体的健康相关生活质量的方法，以及选择适合于这种治疗的个体的方法。使用SLE稳定或改善与健康有关的个体生活质量的一种方法涉及有效量的dsDNA表位的施用，例如以表位呈递载体或表位呈递价态平台分子的形式，例如LJP 394，给个人。本发明进一步提供一种稳定或改善具有SLE的个体的健康相关生活质量的方法，其涉及降低个体中SLE相关抗体的水平，任选地通过向个体施用dsDNA表位。此外，还提供了筛选患者的方法。还提供了在本发明的方法中有用的试剂盒。

8. 发明申请

US20070191297A1 METHODS OF TREATING AND MONITORING SYSTEMIC LUPUS ERYTHEMATOSUS IN INDIVIDUALS 审中-公开
标题翻译：在个体中治疗和监测系统性红斑狼疮的方法
公开(公告)号：US20070191297A1
公开(公告)日：2007-08-16
申请号：US11565467
申请日：2006-11-30
申请人： Matthew LINNIK , Tenshang JOH
发明人： Matthew LINNIK , Tenshang JOH
IPC分类号： A61K48/00 , C07H21/04
CPC分类号： C12N15/113 , A61K38/00 , A61K47/6843 , C12N2310/13 , C12N2310/351
摘要： The invention provides methods for treating SLE including renal SLE and methods of reducing risk of renal flare in individuals with SLE, and methods of monitoring such treatment. One method of treating SLE including renal SLE and reducing risk of renal flare in an individual with SLE involves the administration of an effective amount of an agent for reducing the level of anti-dsDNA antibody (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) to the individual. The invention further provides a method of treating renal flare and reducing risk of renal flare in an individual with SLE involving the reduction of the level of circulating anti-dsDNA antibodies in the individual and maintaining sustained reduction of circulating anti-dsDNA antibodies, optionally through administration of a dsDNA epitope to the individual.
摘要翻译：本发明提供了治疗包括肾SLE在内的SLE的方法和降低患有SLE的个体的肾眩晕风险的方法，以及监测这种治疗的方法。在SLE患者中治疗SLE的一种方法包括肾SLE和降低肾闪烁的风险包括给予有效量的用于降低抗dsDNA抗体水平的试剂（如dsDNA抗体的形式表位呈递载体或表位呈递价态平台分子，如LJP 394）。本发明进一步提供了一种治疗肾眩晕并降低患有SLE的个体的肾脏火炬的风险的方法，其涉及降低个体中循环抗dsDNA抗体的水平，并且可以任选地通过施用维持循环抗dsDNA抗体的持续降低的dsDNA表位。

9. 发明申请

US20050096360A1 Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases 审中-公开
标题翻译：氨基脲敏感性胺氧化酶（SSAO）和VAP-1介导的粘附抑制剂可用于治疗疾病
公开(公告)号：US20050096360A1
公开(公告)日：2005-05-05
申请号：US10913253
申请日：2004-08-06
申请人： Luisa Salter-Cid , Eric Wang , Keith Cockerill , Matthew Linnik , Edward Victoria
发明人： Luisa Salter-Cid , Eric Wang , Keith Cockerill , Matthew Linnik , Edward Victoria
IPC分类号： C07C211/26 , C07C211/27 , C07C239/20 , C07C243/18 , A61K31/44 , A61K31/15
CPC分类号： C07C239/20 , C07C211/26 , C07C243/18 , C07C2601/02
摘要： Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylhydrazine compounds, hydroxylamine (aminooxy) compounds, and other compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis.
摘要翻译：提供了使用组合物治疗炎性疾病和免疫疾病的组合物和方法。公开了作为氨基脲敏感性胺氧化酶（SSAO）和/或血管粘附蛋白1（VAP-1）的抑制剂的烯丙基肼化合物，羟胺（氨氧基）化合物和其它化合物。这些化合物在治疗炎症和炎症反应以及治疗包括多发性硬化的几种疾病中具有治疗效用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式